Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: A global model applied to Ghana, Thailand, and the Netherlands

Transfusion

Volumn 49, Issue 12, 2009, Pages 2729-2742

  Van Hulst, Marinus ^{a,b,c,d,e,f,g,h,i}   Hubben, Gijs A A ^{a,b,c,d,e,f,g,h,i}   Sagoe, Kwamena W C ^{a,b,c,d,e,f,g,h,i}   Promwong, Charupon ^{a,b,c,d,e,f,g,h,i}   Permpikul, Parichart ^{a,b,c,d,e,f,g,h,i}   Fongsatitkul, Ladda ^{a,b,c,d,e,f,g,h,i}   Glynn, Diarmuid M ^{a,b,c,d,e,f,g,h,i}   Sibinga, Cees T Smit ^{a,b,c,d,e,f,g,h,i}   Postma, Maarten J ^{a,b,c,d,e,f,g,h,i}  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

^c Health Economics Consultancy and Technology Assessments (HECTA)   (Netherlands)

^d BaseCase GmbH Decision Support Software   (Switzerland)

^e UNIVERSITY OF GHANA   (Ghana)

^f PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h Faculty of Medicine Chiang Mai University   (Thailand)

ⁱ Sanquin Consulting Services   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGED; ANTIBODY SCREENING; ARTICLE; BLOOD DONOR; COMPUTER INTERFACE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; GHANA; HEALTH ECONOMICS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NETHERLANDS; NUCLEIC ACID AMPLIFICATION; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY ANALYSIS; THAILAND; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

BLOOD BANKS; BLOOD DONORS; BLOOD TRANSFUSION; COMMUNICABLE DISEASE CONTROL; COST-BENEFIT ANALYSIS; DISEASE TRANSMISSION, INFECTIOUS; GHANA; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERNET; MODELS, ECONOMETRIC; NETHERLANDS; RISK ASSESSMENT; RISK FACTORS; THAILAND; WORLD HEALTH;

EID: 71849086840     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02351.x     Document Type: Article

References (60)

1. Van Hulst M, De Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002 83 : 146 55.
2. Custer B. Economic analyses of blood safety and transfusion medicine interventions: a systematic review. Transfus Med Rev 2004 18 : 127 43.
3. Sarkodie F, Adarkwa M, du-Sarkodie Y, Candotti D, Acheampong JW, Allain JP. Screening for viral markers in volunteer and replacement blood donors in West Africa. Vox Sang 2001 80 : 142 7.
4. Kitayaporn D, Bejrachandra S, Chongkolwatana V, Chandanayingyong D, Weniger BG. Potential deferral criteria predictive of human immunodeficiency virus positivity among blood donors in Thailand. Transfusion 1994 34 : 152 7.
5. Janssen MP, Van Der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006 46 : 956 65.
6. Nantachit N, Thaikruea L, Thongsawat S, Leetrakool N, Fongsatikul L, Sompan P, Fong YL, Nichols D, Ziermann R, Ness P, Nelson KE. Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand. Transfusion 2007 47 : 1803 8.
7. Van Hulst M, Sagoe KW, Vermande JE, van de Schaaf IP, van der Tuuk Adriani WP, Torpey K, Ansah J, Mingle JA, Smit Sibinga CT, Postma MJ. Cost-effectiveness of HIV screening of blood donations in Accra (Ghana). Value Health 2008 11 : 809 19.
8. Tynell E, Norda R, Shanwell A, Bjorkman A. Long-term survival in transfusion recipients in Sweden, 1993. Transfusion 2001 41 : 251 5.
9. Cobain TJ, Vamvakas EC, Wells A, Titlestad K. A survey of the demographics of blood use. Transfus Med 2007 17 : 1 15.
10. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996 334 : 1685 90.
11. Laperche S, Elghouzzi MH, Morel P, Asso-Bonnet M, Le Marrec N, Girault A, Servant-Delmas A, Bouchardeau F, Deschaseaux M, Piquet Y. Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? Transfusion 2005 45 : 1965 72.
12. Sanquin Blood Supply Foundation. Sanquin Annual Report 2006. Amsterdam : Sanquin Blood Supply Foundation 2007.
13. Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997 11 : 155 72.
14. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
15. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, Morel P, van Drimmelen H, David B, Lelie N, De Micco P. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels. Transfusion 2009 49 : 301 10.
16. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006 36 Suppl 1 : S23 9.
17. Field SP, Allain JP. Transfusion in Sub-Saharan Africa - does a Western model fit? J Clin Pathol 2007 60 : 1073 5.
18. Fang CT, Field SP, Busch MP, Heyns AP. Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing. Vox Sang 2003 85 : 9 19.
19. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K. HBV NAT positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005 88 : 77 86.
20. Korelitz JJ, Busch MP, Kleinman SH, Williams AE, Gilcher RO, Ownby HE, Schreiber GB. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 1997 37 : 634 40.
21. Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion 1994 34 : 464 70.
22. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003 43 : 721 9.
23. Crowley S, Tognarini D, Desmond P, Lees M, Saal G. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002 17 : 153 64.
24. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997 127 : 855 65.
25. Borkent-Raven BA, Janssen MP, Van Der Poel CL, de Wit GA, Bonsel GJ, van Hout BA. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands. Transfusion 2009 49 : 311 9.
26. WHO. Ghana reported immunization coverage cited 2007 May 10]. Available from: http://www.who.int/immunization-monitoring/en/globalsummary/timeseries/ tscoveragebycountry.cfm?C=GHA
27. Dentinger CM, McMahon BJ, Butler JC, Dunaway CE, Zanis CL, Bulkow LR, Bruden DL, Nainan OV, Khristova ML, Hennessy TW, Parkinson AJ. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 2005 24 : 786 92.
28. Milne A, West DJ, Chinh DV, Moyes CD, Poerschke G. Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J Med Virol 2002 67 : 327 33.
29. Allain JP, Candotti D, Soldan K, Sarkodie F, Phelps B, Giachetti C, Shyamala V, Yeboah F, Anokwa M, Owusu-Ofori S, Opare-Sem O. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 2003 101 : 2419 25.
30. Chongsrisawat V, Yoocharoen P, Theamboonlers A, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, Paupunwatana S, Chaiear K, Khwanjaipanich S, Poovorawan Y. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006 11 : 1496 502.
31. WHO. Thailand reported immunization coverage cited 2007 May 10]. Available from: http://www.who.int/immunization-monitoring/en/globalsummary/ timeseries/tscoveragebycountry.cfm?C=THA
32. Boot HJ, Schouls L, Hahne S, Berbers GA, van de Laar MJ, Kimman TG Vaccination against pneumococci and hepatitis B in the Dutch National Immunisation Programme Ned Tijdschr Geneeskd 2007 151 : 172 6.
33. Veldhuijzen IK, Conyn-van Spaendoncka MA, Dorigo-Zetsmab JW. Seroprevalentie van hepatitis B en C in de Nederlandse bevolking [Seroprevalence of hepatitis B and C in the Dutch population Infect Bull 1999 10 : 182 4.
34. Wasem J, Sroczynski G, Aidelsburger P, Buchberger B, Hessel F, Conrads-Frank A, Peters-Blochinger A, Kurth BM, Wong JB, Rossol S, Siebert U Health economics of chronic infectious diseases: the example of hepatitis C Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2006 49 : 57 63.
35. Siebert U, Sroczynski G, German Hepatitis C Model (GEHMO) Group, HTA-Expertenpanels für Hepatitis C. Antivirale Therapie bei Patienten mit chronischer Hepatitis C in Deutschland. Medizinische und ökonomische Evaluation der initialen Kombinationstherapie mit Interferon/Peginterferon und Ribavirin. Köln : DIMDI 2003.
36. UNAIDS Reference Group on Estimates, Modelling and Projections. Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: recommendations of the UNAIDS reference group on estimates, modelling and projections. AIDS 2002 16 : W1 14.
37. Predicting the failure of 3 by 5. Lancet 2005 365 : 1597.
38. Ministry of Health/Ghana Health Service. HIV/AIDS in Ghana. Accra : National AIDS/STI Control Programme/Ghana Health Service 2005.
39. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM, Egger M. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005 366 : 378 84.
40. Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piche A, Hankins CA. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS 2004 18 : 2411 8.
41. Torpey EK. Estimating the cost of HIV related clinical care services. Accra : Family Health International 2003.
42. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006 20 : 1181 9.
43. UNAIDS/WHO. Thailand country profile cited 2007 Nov 22]. Available from: http://apps.who.int/globalatlas/predefinedReports/EFS2008/short/ EFSCountryProfiles2008-TH.pdf
44. WHO Statistical Information System (WHOSIS). Life Tables for 191 Countries, Ghana, 2006 cited 2007 Jun 1]. Available from: http://apps.who.int/ whosis/database/life-tables/life-tables.cfm
45. Murray CJ, Lopez AD. The global burden of disease. A comprehensive assesment of mortality and disability for diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge (MA) : Harvard University Press 1996.
46. WHO. Investing in health research and development: report of the ad hoc committee on health research relating to future intervention options. Geneva : WHO 1996.
47. World Bank. World Development Report 1993. New York : Oxford University Press 1993.
48. Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002 359 : 1635 43.
49. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ 2005 331 : 1431 7.
50. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. N Engl J Med 2006 355 : 1141 53.
51. Wang B, Schreiber GB, Glynn SA, Kleinman S, Wright DJ, Murphy EL, Busch MP. Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors? Transfusion 2005 45 : 1089 96.
52. Candotti D, Sarkodie F, Allain JP. Residual risk of transfusion in Ghana. Br J Haematol 2001 113 : 37 9.
53. Phikulsod S, Oota S, Tirawatnapong T, Sakuldamrongpanich T, Chalermchan W, Louisirirotchanakul S, Tanprasert S, Chongkolwatana V, Kitpoka P, Phanuphak P, Wasi C, Nuchprayoon C the Working Group for NAT Study in Thai Blood Donations. One-year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations. Transfusion 2009 49 : 1126 35.
54. Moore A, Herrera G, Nyamongo J, Lackritz E, Granade T, Nahlen B, Oloo A, Opondo G, Muga R, Janssen R. Estimated risk of HIV transmission by blood transfusion in Kenya. Lancet 2001 358 : 657 60.
55. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA 1994 272 : 1210 4.
56. Jackson BR, AuBuchon JP, Birkmeyer JD. Update of cost-effectiveness analysis for solvent-detergent-treated plasma. JAMA 1999 282 : 329.
57. UNAIDS/WHO. Epidemiological fact sheets on HIV and AIDS for Ghana, 2008 update. [cited 2009 Jun 1]. Available from: http://apps.who.int/globalatlas/ predefinedReports/EFS2008/full/EFS2008-GH.pdf
58. UNAIDS/WHO. Epidemiological fact sheets on HIV and AIDS for Thailand, 2008 update. [cited 2009 Jun 1]. Available from: http://apps.who.int/ globalatlas/predefinedReports/EFS2008/full/EFS2008-TH.pdf
59. UNAIDS/WHO. Epidemiological fact sheets on HIV and AIDS for the Netherlands, 2008 update. [cited 2009 Jun 1]. Available from: http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008-NL.pdf
60. Vipa T, Weer P, Varu D, Duan S, Yupa W, Amna C, Pote A, Than S. Viral hepatitis infections among dialysis patients: Thailand registry report. Nephrology 2007 12: 399 405.